Literature DB >> 32312768

Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.

Philippe Guilpain1,2, Clément Le Bihan3, Vincent Foulongne4, Patrice Taourel5, Nathalie Pansu3, Alexandre Thibault Jacques Maria1,2, Boris Jung6,7, Romaric Larcher6,7, Kada Klouche6,7, Vincent Le Moing3.   

Abstract

Entities:  

Keywords:  communicable diseases, imported; granulomatosis with polyangiitis; hydroxychloroquine; rituximab; systemic vasculitis

Mesh：

Substances：

Year:  2020        PMID： 32312768     DOI： 10.1136/annrheumdis-2020-217549

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  47 in total

1.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2020-06-27       Impact factor: 9.079

2.  B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?

Authors:  Puja Mehta; Joanna C Porter; Rachel C Chambers; David A Isenberg; Venkat Reddy
Journal:  Lancet Rheumatol       Date:  2020-07-31

3.  COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm.

Authors:  Pascale Daniel; Marc Raad; Rami Waked; Jacques Choucair; Moussa Riachy; Fady Haddad
Journal:  Eur J Case Rep Intern Med       Date:  2020-09-24

4.  Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.

Authors:  Rohan M Prasad; Shaurya Srivastava; Enhua Wang; Jason Z Liu; Rakesh Gami; Ayat Abdelgadir; Akhil Sharma; Sumugdha Rayamajhi; Richa Tikaria
Journal:  Perm J       Date:  2021-10-29

5.  Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination.

Authors:  Yohei Funakoshi; Kimikazu Yakushijin; Goh Ohji; Wataru Hojo; Hironori Sakai; Marika Watanabe; Akihito Kitao; Yoshiharu Miyata; Yasuyuki Saito; Shinichiro Kawamoto; Katsuya Yamamoto; Mitsuhiro Ito; Taiji Koyama; Yoshinori Imamura; Naomi Kiyota; Hiroshi Matsuoka; Yasuko Mori; Hironobu Minami
Journal:  Vaccines (Basel)       Date:  2022-06-17

Review 6.  Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.

Authors:  Lai-Shan Tam; Yoshiya Tanaka; Rohini Handa; Zhanguo Li; Jose Paulo Lorenzo; Worawit Louthrenoo; Catherine Hill; Kevin Pile; Philip C Robinson; Leonila F Dans; Li Yang Hsu; Sang-Min Lee; Jiacai Cho; A T M Tanveer Hasan; Babur Salim; Saba Samreen; Syahrul Sazliyana Shaharir; Priscilla Wong; Jeffrey Chau; Debashish Danda; Syed Atiqul Haq
Journal:  Int J Rheum Dis       Date:  2021-05-04       Impact factor: 2.454

7.  COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.

Authors:  Jessica M Jones; Aiman J Faruqi; James K Sullivan; Cassandra Calabrese; Leonard H Calabrese
Journal:  Pathog Immun       Date:  2021-05-14

8.  SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.

Authors:  Daniel Mrak; Selma Tobudic; Maximilian Koblischke; Marianne Graninger; Helga Radner; Daniela Sieghart; Philipp Hofer; Thomas Perkmann; Helmuth Haslacher; Renate Thalhammer; Stefan Winkler; Stephan Blüml; Karin Stiasny; Judith H Aberle; Josef S Smolen; Leonhard X Heinz; Daniel Aletaha; Michael Bonelli
Journal:  Ann Rheum Dis       Date:  2021-07-20       Impact factor: 19.103

Review 9.  Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).

Authors:  Cara D Varley; Kevin L Winthrop
Journal:  Curr Rheumatol Rep       Date:  2021-07-16       Impact factor: 4.592

Review 10.  Rheumatological complications of Covid 19.

Authors:  Hannah Zacharias; Shirish Dubey; Gouri Koduri; David D'Cruz
Journal:  Autoimmun Rev       Date:  2021-07-05       Impact factor: 9.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.